



Published in final edited form as:

*Chem Commun (Camb)*. 2018 February 20; 54(16): 2000–2003. doi:10.1039/c8cc00167g.

## Real-Time Monitoring of the Aggregation of Alzheimer's Amyloid- $\beta$ by $^1\text{H}$ Magic Angle Spinning NMR Spectroscopy

Jian Wang<sup>a,b,†</sup>, Tomoya Yamamoto<sup>a,b,†</sup>, Jia Bai<sup>a,b</sup>, Sarah J. Cox<sup>b</sup>, Kyle J. Korshavn<sup>a,b</sup>, Martine Monnette<sup>c</sup>, and Ayyalusamy Ramamoorthy<sup>a,b,\*</sup>

<sup>a</sup>Biophysics Program, The University of Michigan, Ann Arbor, MI 48109-1055, USA


<sup>b</sup>Department of Chemistry, The University of Michigan, Ann Arbor, MI 48109-1055, USA

<sup>c</sup>Bruker Canada Ltd, 2800 High Point Drive, Milton, Ontario, Canada L9T 5G5

### Abstract

Proton magic-angle-spinning NMR used for real-time analysis of amyloid aggregation reveals that the mechanical rotation of  $\text{A}\beta_{1-40}$  monomers increases the rate of formation of aggregates, and that the increasing lag-time with peptide concentration suggests the formation of growth-incompetent species. EGCG's ability to shift off-pathway aggregation is also demonstrated.

### Graphical Abstract



The accumulation of misfolded proteins is the hallmark of numerous aging-related amyloid diseases including Alzheimer's disease (AD),<sup>1,2</sup> type II diabetes,<sup>3</sup> and Parkinson's disease.<sup>4</sup> These disorders are called amyloidosis, which are major threats to quality of life in modern society and global economy.<sup>5,6</sup> It is believed that the aggregation process starts from monomers, followed by the formation of oligomers and then ends with long fibrous end products.<sup>7</sup> Biophysical methods such as thioflavin T (ThT) fluorescence, Circular Dichroism (CD), Dynamic Light Scattering (DLS), and Transmission Electron Microscopy (TEM) are typically used to study the aggregation process.<sup>5,8</sup> While these measurements are highly valuable in providing the rate, secondary structure, and the size of aggregates in a time

<sup>†</sup>These authors contributed equally to this study.

Electronic Supplementary Information (ESI) available: Experimental procedure, The sequence of  $\text{A}\beta_{40}$  peptide, chemical structure of EGCG, 1D  $^1\text{H}$  spectrum and detailed signal decay obtained in  $^1\text{H}$  NMR experiment. See DOI: 10.1039/x0xx00000x

#### Conflicts of interest

The authors declare no competing financial interests.

course manner, they cannot reveal specific molecular-level interactions that drive the aggregation process, and the formation of oligomeric intermediates cannot be detected. Due to lack of appropriate detection tools, a detailed knowledge of the aggregation process at molecular-level is still missing, which is of crucial importance to understand the pathogenic mechanism of amyloid proteins and to develop potential therapeutic treatments for amyloidosis. As aggregation progressively develops, a variety of species can coexist with conversions between them.<sup>8</sup> The heterogeneous and transient nature of these oligomeric species pose tremendous challenges to traditional high-resolution techniques. Commonly used biophysical techniques fall short in probing residue specific changes; and although solution NMR spectroscopy is suitable for tracking the aggregation in real time, and molecular level interactions,<sup>9,10</sup> the aggregation doesn't usually proceed efficiently for most unseeded samples under quiescent and small-concentration conditions.<sup>11-13</sup> Although physical effects such as shear stress,<sup>14</sup> pressure jump<sup>15</sup> and centrifugation<sup>16</sup> during the course of measurement enables real-time analysis with NMR, they are still difficult to apply to monitor a real-time aggregation process. In addition, solution NMR spectroscopy has limitations in detecting species that undergo slow motion such as semi-solids or solid aggregates. On the other hand, solid-state MAS NMR provided valuable insights into the formation of oligomers and fibers for amyloid proteins.

In this study, we report the use of <sup>1</sup>H MAS NMR experiments to monitor the aggregation kinetics of amyloid-forming proteins. By measuring the reduction in peak intensities in the <sup>1</sup>H NMR spectrum due to A $\beta$ <sub>1-40</sub> aggregation (Figure S1), the rate of change in the mobility for each functional group of the peptide in real time was estimated. To test if this method can be used to monitor amyloid aggregation in presence of inhibitors, experiments were performed by monitoring the effect of EGCG (Figure S2), and found that the binding of EGCG to A $\beta$ <sub>1-40</sub> resulted in the formation of unstructured oligomers by inhibiting the formation of fibers which is in accordance to previous studies.<sup>17-19</sup>

<sup>1</sup>H NMR spectra of A $\beta$ <sub>1-40</sub> in pH 7.4 phosphate buffer were collected in a time-course manner under 5 kHz MAS (Figure S3). Peak intensities for different chemical groups of the peptide as a function of aggregation time were measured (Figure S4); two representative plots are shown in Figure 1. The total signal intensity of A $\beta$ <sub>1-40</sub> was found to decrease over time, and the rates of intensity decays were found to be similar for both aromatic and aliphatic protons under the experimental conditions employed as shown in Figure 1. The observed decrease in the signal intensity is attributed to peptide aggregation under the mechanical rotation of the sample. Dipolar interactions among protons associated with large non-monomeric species must increase sufficiently to be the major cause for the fast spin-spin relaxation as reflected in the line broadening, and thus contributing to the loss of signal intensities. The total weights of the MAS rotor (with the sample) measured before and after NMR experiments were found to be identical suggesting that the loss of signal intensities cannot be due to water evaporation or leakage of A $\beta$ <sub>40</sub> solution. At the same time, no changes were observed from 1D <sup>1</sup>H NMR spectra (Figure S5) and 2D 1H/15N SOFAST-HMQC or 2D <sup>1</sup>H/<sup>15</sup>N HSQC spectra of the A $\beta$ <sub>40</sub> peptide solution suggesting that the peptide does not aggregate at least for 24 hours under room temperature for a peptide concentration at least up to 50  $\mu$ M under quiescent conditions, which has reported in previous studies.<sup>12,13</sup> Therefore, our experimental results shown in Figure 1 indicate that

$A\beta_{1-40}$  aggregation is accelerated with the mechanical rotation of the sample under MAS condition. Since the MAS rotor was fully occupied by the  $A\beta_{1-40}$  solution sample without any air-water interface and the entire sample was spun at the magic angle, it is less likely that the rate of collision among monomers in the MAS rotor is different from that in a static sample. But, the fact that aggregation of monomers was observed only under spinning suggests that the initial sample (i.e., at time zero) might have contained a small amount of non-monomeric species. Even though the sample preparation was strictly and reproducibly followed to produce monomers and proven to be successful (based on ThT experiments, TEM images and solution NMR experiments), our results suggest that the presence of even a very small amount of non-monomeric aggregates can influence the rate of collision among monomers under spinning.<sup>20-22</sup>

Next, we investigated the aggregation of  $A\beta_{1-40}$  in presence of EGCG (1:1  $A\beta_{1-40}$  to EGCG molar ratio) using  $^1H$  MAS experiment as explained above. 1D  $^1H$  NMR spectra acquired at several different time points are shown in Figures 2 and S6. The  $K_D$  value for the binding between  $A\beta_{1-40}$  monomer and EGCG has been reported as  $47 \mu M$ <sup>23</sup> and the analysis of chemical shift perturbation indicates that most of EGCG binds to  $A\beta_{1-40}$  under the condition used in this study.<sup>24</sup> Similar to the observation for  $A\beta_{1-40}$  without EGCG presented above, signal intensities of  $A\beta_{1-40}$  decreased with time, however, in the presence of EGCG the signal from aromatic protons decreased faster than that from aliphatic protons of the peptide (Figure 2B). In addition, the signals from EGCG decreased in intensity rapidly with time (Figure 2C), which suggests the interaction between  $A\beta_{1-40}$  and EGCG is stronger than the interactions driving the self-aggregation of  $A\beta_{1-40}$ . This observation is in agreement with a previous study that showed EGCG's ability to push  $A\beta_{1-40}$  to form off-pathway oligomers.<sup>17</sup> At the same time, it is interesting to note that the aromatic protons of  $A\beta_{1-40}$  showed a higher rate of decrease in signal intensity in the presence of EGCG than in its absence suggesting that the interactions between  $A\beta_{1-40}$  and EGCG are predominantly  $\pi$ - $\pi$  interactions. This observation is in agreement with a previously reported study on the role of  $\pi$ - $\pi$  interaction on the amyloid aggregation of amyloid-beta.<sup>25</sup>

Another noteworthy observation is the appearance of new peaks (marked as O1 and O2 in Figure 2A), which were not observed for  $50 \mu M$   $A\beta_{1-40}$  without EGCG. These peaks exhibited a significant increase in intensity with time (Figure 2D). It is likely that these new peaks originate from  $A\beta_{1-40}$  due to the binding with EGCG or could be due to the formation of oligomeric species. To clarify the origin of these peaks, we examined various concentrations of  $A\beta_{1-40}$  samples in the absence of EGCG. To our surprise, these peaks appeared for  $A\beta_{1-40}$  only at lower concentrations ( $5 \mu M$   $A\beta_{1-40}$  shown in Figure S7). Therefore, the appearance of the new rising peaks (labeled as O in Figure 2A) may not be due to the binding between  $A\beta_{1-40}$  and EGCG.

TEM images were obtained to check the morphologies of different  $A\beta_{1-40}$  samples after NMR measurements. As shown in Figure 4,  $A\beta_{1-40}$  samples in the absence and presence of EGCG display distinct morphologies. Oligomers and small fibers were observed for  $50 \mu M$   $A\beta_{1-40}$  in the absence of EGCG (Figure 3A), whereas amorphous structures were observed in the presence of EGCG (Figure 3B), suggesting that EGCG effectively inhibits  $A\beta_{1-40}$  fibril formation in agreement with previous studies.<sup>26</sup> Similar amorphous structures were

also observed for 5  $\mu\text{M}$   $\text{A}\beta_{1-40}$  although no EGCG was present in the sample (Figure 3C). Since all new rising peaks (labeled as O in Figure 2) were detected only for amorphous  $\text{A}\beta_{1-40}$  samples, we can assign these peaks to unstructured oligomers which are precursors of amorphous aggregates observed in the TEM images.

In order to understand the effect of peptide concentration on two different types of aggregate formation, experiments were performed to monitor the aggregation kinetics at various concentrations of  $\text{A}\beta_{1-40}$  (Figure 4A). The dephasing rate was analyzed based on exponential fitting equation ( $y=(1-A)*\exp(-b*x)+A$ ). In this equation, parameters A and b are the asymptotic value which stands for the proportion that remains as monomer after saturation, and the rate of decay which stands for the rate of aggregation, respectively. The parameters under each condition is shown in Figure 4B. The observed concentration dependence under MAS is contrary to the conventional understanding of amyloid aggregation; the decreasing rate of signal intensity is higher for a lower concentration of the peptide, where the formation of amorphous aggregates is preferred; this is similar to the previously reported disordered oligomers of  $\text{A}\beta_{1-40}$ .<sup>27</sup> This observation could be due to the formation of growth incompetent off pathway aggregates as reported for other amyloid systems.<sup>28-30</sup>

In conclusion, we have shown that  $^1\text{H}$  MAS NMR can be used to monitor the real-time aggregation process of an amyloid protein. In this approach, the experimentally measured rates of signal intensity decays caused by the un-averaged dipolar couplings among protons provided a measurement of the rate of peptide aggregation under different conditions. Some residue-specific kinetic information was obtained through the aggregation time courses, and the role of strong  $\pi$ - $\pi$  interaction between EGCG and  $\text{A}\beta_{1-40}$  in shifting  $\text{A}\beta_{1-40}$  aggregation off-pathway is also reported. Therefore, this simple NMR approach could be used to distinguish the specific molecular interactions contributing to the aggregation process. In addition, we believe that the small amount of peptide required and the fast data collection would enable high-resolution structural studies on amyloid proteins, especially the short-lived oligomeric intermediates that exhibit the maximum cellular toxicity.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

This study was supported by funds from NIH (AG048934 to A. R.). T.Y. was supported by NIH funds and overseas Postdoctoral Fellowship from Uehara Memorial Foundation.


## Notes and references

1. Jakob-Roetne R, Jacobsen H. *Angew Chem Int Ed.* 2009; 48:3030.
2. Hardy J, Selkoe DJ. *Science.* 2002; 297:353. [PubMed: 12130773]
3. Stumvoll M, Goldstein BJ, van Haeften TW. *The Lancet.* 2005; 365:1333.
4. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. *Nature.* 1997; 388:839. [PubMed: 9278044]
5. Chiti F, Dobson CM. *Annu Rev Biochem.* 2006; 75:333. [PubMed: 16756495]

6. Stefani M, Dobson CMJ. *Mol Med*. 2003; 81:678.
7. Benilova I, Karran E, De Strooper B. *Nat Neurosci*. 2012; 15:349. [PubMed: 22286176]
8. Levine H 3rd. *Protein Sci*. 1993; 2:404. [PubMed: 8453378]
9. Balbach J, Forge V, van Nuland NA, Winder SL, Hore PJ, Dobson C. *Nat Struct Mol Biol*. 1995; 2:865.
10. Killick TR, Freund SM, Fersht AR. *Protein Sci*. 1999; 8:1286. [PubMed: 10386878]
11. Suzuki Y, Brender JR, Soper MT, Krishnamoorthy J, Zhou Y, Ruotolo BT, Kotov NA, Ramamoorthy A, Marsh NG. *Biochemistry*. 2013; 52:1903. [PubMed: 23445400]
12. Fawzi NL, Ying J, Torchia DA, Clore GM. *J Am Chem Soc*. 2010; 132:9948. [PubMed: 20604554]
13. Yan Y, Wang CA. *J Mol Biol*. 2006; 364:853. [PubMed: 17046788]
14. Morimoto D, Walinda E, Iwakawa N, Nishizawa M, Kawata Y, Yamamoto A, Shirakawa M, Scheler U, Sugase K. *Anal Chem*. 2017; 89:7286. [PubMed: 28665116]
15. Kamatari Y, Yokoyama S, Tachibana H, Akasaka K. *J Mol Biol*. 2005; 349:916. [PubMed: 15907935]
16. Bertini I, Gallo G, Korsak M, Luchinat C, Mao J, Ravera E. *Chembiochem*. 2013; 14:1891. [PubMed: 23821412]
17. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE. *Nat Struct Mol Biol*. 2008; 15:558. [PubMed: 18511942]
18. Amo J, Fink U, Dasari M, Grelle G, Wanker EE, Bieschke J, Reif B. *J Mol Biol*. 2012; 421:517. [PubMed: 22300765]
19. Suzuki Y, Brender JR, Hartman K, Ramamoorthy A, Marsh NG. *Biochemistry*. 2012; 51:8154. [PubMed: 22998665]
20. Nag S, Sarkar B, Bandyopadhyay A, Sahoo B, Sreenivasan VKA, Kombrabail M, Muralidharan C, Maiti S. *J Biol Chem*. 2011; 286:13827. [PubMed: 21349839]
21. Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. *Proc Natl Acad Sci USA*. 1996; 93:1125. [PubMed: 8577726]
22. Brender JR, Krishnamoorthy J, Sciacca MFM, Vivekanandan S, D'Urso L, Chen J, La Rosa C, Ramamoorthy A. *J Phys Chem B*. 2015; 119:2886. [PubMed: 25645610]
23. Hyung S-J, DeToma AS, Brender JR, Lee S, Vivekanandan S, Kochi A, Choi J-S, Ramamoorthy A, Ruotolo BT, Lim MH. *Proc Natl Acad Sci USA*. 2013; 110:3743. [PubMed: 23426629]
24. Ahmed R, VanSchouwen B, Jafari N, Ni X, Ortega J, Melacini G. *J Am Chem Soc*. 2017; 139:13720. [PubMed: 28841302]
25. Cohen T, Frydman-Marom A, Rechter M, Gazit E. *Biochemistry*. 2006; 45:4727. [PubMed: 16605241]
26. Choi Y-T, Jung C-H, Lee S-R, Bae J-H, Baek W-K, Suh M-H, Park J, Park C-W, Suh S-I. *Life Sci*. 2001; 70:603. [PubMed: 11811904]
27. Kotler SA, Brender JR, Vivekanandan S, Suzuki Y, Yamamoto K, Monette M, Krishnamoorthy J, Walsh P, Cauble M, Holl MMB, Marsh ENG, Ramamoorthy A. *Sci Rep*. 2015; 5:11811. [PubMed: 26138908]
28. Kashchiev D. *J Phys Chem B*. 2017; 121:35. [PubMed: 28029261]
29. Kamgar-Parsi K, Hong L, Naito A, Brooks CL, Ramamoorthy A. *J Biol Chem*. 2017; 292:14963. [PubMed: 28739873]
30. Young LJ, Schierle GSK, Kaminski C. *Phys Chem Chem Phys*. 2017; 19:27987. [PubMed: 29026905]




**Figure 1.** Real-time monitoring of  $A\beta_{1-40}$  monomer depletion under MAS. Experimentally measured  $^1\text{H}$  NMR signal intensities for selected aliphatic and aromatic resonances of freshly prepared  $50\ \mu\text{M}$   $A\beta_{40}$  as a function of time under 5 kHz MAS and 298 K. Additional experimental results showing the decay of monomer peaks are shown in Figure S4. Time=0 was the starting time of NMR data acquisition, which is <10 minutes from the fresh sample preparation.



**Figure 2.  $A\beta_{1-40}$  monomer depletion promoted by EGCG**


(A) 1D  $^1H$  NMR spectra of  $50 \mu M$   $A\beta_{1-40}$  in presence of  $50 \mu M$  EGCG obtained at the indicated times under 5 kHz MAS and 298 K. (B, C, D) Change in  $^1H$  signal intensities for selected aliphatic and aromatic resonances of  $A\beta_{1-40}$  (B), EGCG (C), and the newly appeared peaks (indicated as O1 and O2) (D). Additional experimental results on the changes in peak intensities are shown in Figures S6 and S7.



**Figure 3.**

TEM images of Aβ<sub>1-40</sub> aggregates. TEM images of 50 μM Aβ<sub>1-40</sub> after spinning for 68 hours in the absence (A) and presence of 50 μM EGCG (1:1 Aβ<sub>1-40</sub>:EGCG molar ratio) after spinning for 42 hours (B). TEM images of 5 μM Aβ<sub>1-40</sub> after spinning for 80 hours (C) and 150 μM Aβ<sub>1-40</sub> under static condition after 48 hours (D).





	A	b
150 $\mu\text{M}$ $\text{A}\beta_{1-40}$	0.73	0.023
50 $\mu\text{M}$ $\text{A}\beta_{1-40}$	0.64	0.020
15 $\mu\text{M}$ $\text{A}\beta_{1-40}$	0.65	0.056
50 $\mu\text{M}$ $\text{A}\beta_{1-40}$ with 50 $\mu\text{M}$ EGCG	0.64	0.064

**Figure 4.**

Concentration dependent monomer decay for  $\text{A}\beta_{40}$ . (A) Aggregation kinetics of  $\text{A}\beta_{1-40}$  measured from  $^1\text{H}$  NMR signal intensity of methyl resonance (0.78 ppm) under 5 kHz MAS for various peptide concentrations. The monomer decay curve was fitted using the equation,  $y=(1-A)*\exp(-b*x)+A$ . The parameters used for the monomer decay curves are given in (B). Additional experimental results on the changes in the peak intensities are shown in Figures S8 and S9 and Table S1.